Tempus AI Starts Mizuho Coverage at $100 PT, Unveils HRD-RNA Algorithm
Tempus AI received an Outperform rating from Mizuho with a $100 price target and revealed its HRD-RNA algorithm, which cut mortality risk in metastatic pancreatic cancer patients. The test will launch later this year after Tempus signed a deal with Median Technologies to distribute eyonis LCS on its Pixel platform.
1. Mizuho Initiates Coverage
Tempus AI was initiated with an Outperform rating by Mizuho and a $100 price target, marking the first formal coverage from this major investment bank. The move reflects confidence in the company’s AI-driven diagnostics platform and growth prospects.
2. New HRD-RNA Algorithm Revealed
The company introduced its HRD-RNA algorithm designed to detect homologous recombination deficiency via gene expression analysis. In a real-world validation, HRD-RNA-positive metastatic pancreatic cancer patients treated with platinum regimens saw a significant mortality risk reduction.
3. Median Technologies Distribution Deal
Tempus signed a non-exclusive agreement with Median Technologies to distribute the eyonis LCS imaging solution through its Pixel platform. The partners will collaborate on implementation, customer onboarding and workflow integration across U.S. imaging providers.
4. Clinical Availability and Outlook
Tempus plans to make the HRD-RNA test clinically available later this year, expanding its molecular diagnostics portfolio. Successful deployment could drive revenue growth and enhance the company’s position in precision oncology.